Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)- October 11-13, 2023 / Milan, Italy
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Real-World Evidence with Five-Year Data (2017–2022) on the use of Cladribine Tablets in Patients with Multiple Sclerosis in England: An Updated Analysis From the CLARENCE Study
Brownlee | Poster #1558/603
A Novel Autoantigen Discovery Platform for the Identification of Diagnostic and Theragnostic Autoantibody Biomarkers in Multiple Sclerosis
DiCillo | Poster #1670/3024
Correlations Between Patient-Reported and Clinical Outcomes in Patients with Multiple Sclerosis in the MS-LINK Outcomes Study Cohort
English | Poster #1652/3059
Investigation of Changes in Lymphocyte Subset Counts and Their Relationship with MRI Outcomes in the MAGNIFY-MS Study
Hodgkinson | Poster# 141/592
Design and Baseline Characteristics of Phase 3, Double-Blind, Randomized Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)
Montalban | Poster #696/1177
Update on Long-Term Safety and Efficacy of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, over 5 Years from an Ongoing Phase 2 Open-Label Extension
Montalban | Poster #706/1280
Real World Treatment Patterns and High Treatment Completion Rate in a Large Cohort of LATAM MS Patients who Received Cladribine Tablets
Negrotto | Poster #1562/1388
Associations Between Cognition, Fatigue, and Work Productivity and Activity Impairment in a US Patient Support Program in Relapsing Multiple Sclerosis
Nicholas | Poster #1192/1039
Real-World Outcomes with Cladribine Tablets in People with Relapsing Multiple Sclerosis
Okuda | Poster #782
The Next Generation Learning Health System for Multiple Sclerosis (Next Gen-MS): Study Design, Demographics, and Analysis of System-Level Variation in Baseline Characteristics
Oliver | Poster #080/871
Time to Qualifying Relapse by Previous Disease-Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets over 2 Years in the CLARIFY-MS Study
Patti | Poster #1165/364
Reduction of Neuroaxonal Damage in Patients with Highly Active Relapsing MS Treated with Cladribine Tablets
Schmierer | Poster #1385/598
Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial
Vermersh | Poster #1193/1191
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: